Market Overview

The broad market is under pressure from a multi-day tech and AI selloff, with chip stocks leading declines after concerns over AI spending sustainability. The Dow, S&P 500, and Nasdaq all fell Tuesday-Wednesday as investors rotated out of semiconductors and mega-cap tech into defensive sectors, healthcare, and consumer staples. FedEx earnings disappointed, adding to the risk-off tone, while the SpaceX IPO frenzy is absorbing retail liquidity.

Claude’s Call

DOWN — The tech selloff has not found a floor yet, with MSFT and NVDA sentiment turning bearish on WSB and no catalyst to arrest the rotation. I expect another leg lower in the S&P 500 today as chipmaker weakness bleeds into broader indices, though healthcare and waste management names may continue to outperform as safe havens.

Top Movers

ALKS (+8.41%) — $51.37 → $56.50 (+10.0% upside) Thesis: Orphan drug designations for alixorexton in both U.S. and Europe create a rare regulatory moat, while the Avadel integration and expanding sleep-medicine portfolio (Lumryz + orexin agonist entering Phase 3) give this a multi-catalyst runway. RSI at 50 means this isn’t overextended — it’s mid-range with fundamental catalysts stacking up. This is a real pipeline inflection, not sector sympathy. Levels: Exit at $56.50 (prior 6-month high area). Support at $47.50 (20-day MA zone).

BFLY (+6.95%) — $8.23 → $9.50 (+15.4% upside) Thesis: The Midjourney Medical partnership is a legitimate game-changer — 40 Ultrasound-on-Chip modules in a full-body scanner prototype, validated by Michael Burry’s attention. The stock is up 45.75% on the week though, RSI at 69.5 is approaching overbought, and this is trading on hype for a pre-revenue partnership. The catalyst is real but the move is getting extended — tread carefully. Levels: Exit at $9.50 (4-year high breakout target). Support at $6.80 (pre-Midjourney announcement level).

EXPE (+6.0%) — $259.73 → $280.00 (+7.8% upside) Thesis: Classic rotation trade — money fleeing tech/AI is landing in beaten-down travel names. RSI at 10.88 signals extreme oversold conditions, making this a textbook mean-reversion bounce. No company-specific catalyst beyond sector rotation and a general “outperforming the Dow” narrative, but the oversold setup provides a technical floor. Levels: Exit at $280 (prior consolidation range). Support at $245 (recent 52-week low area).

MEDP (+4.68%) — $495.64 → $530.00 (+6.9% upside) Thesis: CRO leader bouncing hard off extreme oversold levels (RSI 8.39 — nearly single digits). Featured in “market-beating stocks” lists and institutional investor letters as a quality compounder. The 55% one-year total return suggests strong underlying business momentum despite the YTD drawdown. This is a high-quality name trading at a discount to its own history. Levels: Exit at $530 (50-day MA recapture zone). Support at $461 (recent low).

NTRA (+4.1%) — $246.46 → $260.00 (+5.5% upside) Thesis: Japan PMDA approval of Signatera MRD test is a concrete international revenue catalyst — first-ever MRD approval in Japan with SRL’s nationwide distribution. RSI at 15.26 screams deeply oversold on a stock with legitimate secular growth in liquid biopsy/precision oncology. The Pirche transplant collaboration adds another growth vector announced today. Levels: Exit at $260 (analyst consensus fair value). Support at $220 (prior multi-month support).

BRBR (+6.13%) — $11.91 → $13.50 (+13.4% upside) Thesis: BellRing Brands is catching a rotation bid as investors flee semiconductors into consumer staples with rock-bottom valuations — forward P/E at 5.62x is absurdly cheap for a profitable shelf-stable food company. RSI at 4.95 is the most oversold stock on this list by far, suggesting a violent snapback is overdue. The r/ValueInvesting thesis post gaining traction adds retail support. Levels: Exit at $13.50 (pre-selloff consolidation). Support at $8.80 (recent low from 6/12).

WGS (+7.0%) — $62.03 → $68.00 (+9.6% upside) Thesis: Extreme oversold bounce (RSI 7.47) after Q1 earnings miss, guidance cut, and class action lawsuits cratered the stock. Hedge fund Casdin loading up $43M and insider buying signal smart money thinks the selloff was overdone. This is a speculative rebound play — the lawsuits add tail risk but the genomics volume growth (34%) is real. Levels: Exit at $68 (50-day MA area). Support at $55 (post-guidance-cut low).

Headlines to Watch

  • Midjourney Medical unveils full-body scanner using Butterfly Network’s chip technology — This is a potential platform shift for medical imaging; BFLY’s semiconductor approach could become an industry standard if Midjourney scales manufacturing.
  • Natera’s Signatera receives first-ever MRD test approval in Japan — International expansion into the world’s third-largest healthcare market opens a significant TAM runway for liquid biopsy.
  • Broader tech and AI selloff continues for second day — Chipmaker weakness (MU, NVDA) is dragging indices lower; watch for contagion into software names or signs of stabilization.
  • FedEx dives on earnings miss — Signals potential economic softening in logistics/shipping that could weigh on industrial names and consumer discretionary.
  • SpaceX ETF halted hours after record IPO — The SPCX saga highlights frothy retail speculation and regulatory risk in thematic ETFs; a cautionary tale for momentum chasers.
  • Mark Zandi warns top 20% now drive 60% of spending — Consumer bifurcation thesis strengthening; favors luxury/premium brands over mass-market retailers.
  • CIBC report on landfill capacity scarcity through 2044 — Structural tailwind for waste names like WCN; pricing power protected by regulatory barriers to new landfill permitting.

Claude’s Top Picks

BRBR (+6.13% today, +34.88% week) — $11.91 → $13.50 (+13.4% upside) Valuation: At 5.6x forward P/E, this is trading at less than half the shelf-stable food peer median (~14x) — screaming CHEAP even accounting for any near-term headwinds. Upside: RSI at 4.95 is historically extreme; mean-reversion alone should carry this 10-15% higher within two weeks, and the rotation out of tech into staples provides sustained bid. Risk: If the broader market selloff accelerates into a true risk-off event, even cheap staples names can get caught in forced liquidation; stop at $10.50.

NTRA (+4.1% today, +11.97% week) — $246.46 → $260.00 (+5.5% upside) Valuation: Trading below analyst consensus of $260 with 30%+ revenue growth — PEG ratio well under 1.5x, which is cheap for a precision medicine leader. Upside: Japan approval + Pirche collaboration announced same day creates a dual-catalyst setup; deeply oversold RSI at 15 means short-covering should provide mechanical lift. Risk: Broad biotech funding environment could tighten if tech selloff creates liquidity withdrawal across growth sectors; stop at $230.

MEDP (+4.68% today, +7.37% week) — $495.64 → $530.00 (+6.9% upside) Valuation: Historically trades at 25-30x forward earnings; if currently near the lower end of that range after YTD -18% drawdown, there’s re-rating potential as CRO demand remains robust. Upside: RSI at 8.39 is absurdly oversold for a profitable, growing business; institutional buying (Turtle Creek) signals smart money accumulating at these levels. Risk: If pharma R&D budgets get cut due to macro uncertainty, CRO spending could decelerate; stop at $460.

ALKS (+8.41% today, +16.5% week) — $51.37 → $56.50 (+10.0% upside) Valuation: Trading at a reasonable multiple for a specialty pharma with four commercial products plus a Phase 3 pipeline asset — not expensive relative to mid-cap biopharma peers. Upside: Orphan drug designations provide 7-year market exclusivity moats; CEO transition typically creates “prove it” rallies as new leadership articulates growth vision. Risk: Integration risk from Avadel acquisition could distract management; sleep-medicine competition (Harmony, Jazz) is intensifying; stop at $47.

Avoid

BFLY (+6.95% today, +45.75% week) — RSI at 69.5 and up nearly 50% in a week on a prototype partnership announcement. The Midjourney catalyst is real but the stock has already priced in significant upside; chasing here at 4-year highs with no revenue contribution yet from this deal is high-risk. Wait for a pullback to $6.50-7.00.

WGS (+7.0% today, RSI 7.47) — Despite the extreme oversold bounce, this company just cut guidance by 12%, has active class action lawsuits, and an insider sold $227K worth of stock. The Casdin buying is notable but the fundamental deterioration (earnings miss + impairment) makes this a falling knife, not a value play. Dead cat bounce probability is high.

LEG (+5.23%) — A rebrand of the automotive division doesn’t change the underlying business challenges. Leggett & Platt is a structurally challenged furniture/bedding component maker with weak Q1 results, and a name change to “Leggett Dynamics” is lipstick on a pig. The implied volatility surge suggests options traders expect more downside.

WSB Sentiment Check

MU — WSB says: MIXED (55% bullish) Claude says: PARTIALLY AGREE — Micron is caught in the chip selloff crossfire but has legitimate AI/HBM demand tailwinds. The mixed sentiment actually feels appropriate — the near-term pain from sector rotation is real, but the secular demand story hasn’t broken. I’d wait for the selling to exhaust before stepping in.

WEN — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — 80% bullish on Wendy’s during a consumer spending bifurcation where the bottom 80% of Americans are falling behind inflation? Fast food is facing traffic declines and input cost pressure. This smells like a meme pump with no fundamental backing. The high upvotes (8,301) with fast food suggest ironic/meme energy, not real conviction.

SPCX — WSB says: BEARISH (30% bullish) Claude says: AGREE — The SpaceX ETF getting halted hours after launch is exactly the kind of regulatory/structural risk that should make investors bearish. This is a vehicle designed to capture hype, not deliver returns. The 30% bullish crowd are the bag-holders-in-waiting.

MSFT — WSB says: BEARISH (30% bullish) Claude says: DISAGREE — Microsoft bearish at these levels feels like peak fear during a tech rotation. MSFT is a cash-flow monster with diversified revenue streams. WSB turning bearish on mega-cap quality names is historically a contrarian buy signal. Unless AI capex ROI truly disappoints in the next 2 quarters, this is overdone pessimism.

NVDA — WSB says: MIXED (55% bullish) Claude says: PARTIALLY AGREE — The mixed read is fair. NVDA is the bellwether of the AI trade, and if AI spending concerns are legitimate, it should underperform near-term. But the 55% bullish crowd is right that the fundamental demand picture hasn’t cracked. I’d be a buyer on a 10%+ pullback from here, not at current levels during active selling.